Quantcast

When cancer strikes the most vulnerable: New Canadian Cancer Society research grant will study ways to improve treatment of neuroblastoma, one of the most common causes of cancer death in children

April 27, 2011

To view the Social Media Release, click here: http://smr.newswire.ca/en/canadian-cancer-society/when-cancer-strikes-the-most-vulnerable

TORONTO, April 27 /PRNewswire/ – A new Canadian Cancer Society-funded study
will investigate the genetic puzzle of a devastating nervous system
cancer that strikes infants, and identify potential new treatments for
the disease. The study is one of 52 new research projects worth more
than $21 million announced today by the Society. The projects cover a
broad spectrum of cancer research from risk reduction to genetic
studies to drug development and palliative care.

“With these new projects, the Canadian Cancer Society continues to
support a vibrant research community that is seeking ways to reduce
cancer risk, reduce cancer deaths and improve the quality of life of
those living with cancer,” says Dr Christine Williams, Director of
Research, Canadian Cancer Society Research Institute. “We’re making
this announcement on our first nationwide Daffodil Day to underscore
the importance of research in the fight against cancer and to remember
those people who are on a cancer journey. We encourage Canadians to
join us by wearing our new daffodil pin.”

Putting together the pieces of the neuroblastoma puzzle
With a grant of $430,302, Dr Meredith Irwin, a researcher and clinician
at The Hospital for Sick Children (SickKids), is leading the
neuroblastoma study. This cancer of the nervous system, which causes
tumours in the spinal cord, abdomen, chest and adrenal glands, is one
of the most common childhood cancers and also one of the most frequent
causes of childhood cancer death.

In her dual role as a scientist working in the lab and a doctor caring
for these young patients and their families, Dr Irwin brings a unique
perspective.

“I feel like I’m fighting the disease in two ways – I’m helping families
through a tremendously difficult time with treatment and support, and
I’m trying to make a difference in how we understand neuroblastoma and
how we can make an impact on this disease,” Dr Irwin says.

There is another reason for Dr Irwin’s curiosity about this disease -
her own cancer journey. “My experience makes me want to answer those
basic biology questions – to know what makes cancer cells tick – so we
can understand the cancers our patients are fighting and what types of
treatment they need.”

Dr Irwin and her research team will use two approaches to better
understand and potentially treat neuroblastoma:

        --  They will study the various genes and proteins involved in
            killing neuroblastoma cells and try to determine how to
            activate these "death pathways".
        --  They will also study neuroblastoma cells that have spread to
            the bone marrow and try to understand how they are different
            from other neuroblastoma tumour cells that have spread to other
            locations in the body. Using this information, they will test
            drugs already used in other diseases to see if they can
            specifically kill neuroblastoma cells in the bone marrow, the
            most frequent site to which the disease spreads.

“Ultimately, what I want to do as a clinician-scientist is to be able to
have a different conversation with children and their parents about a
neuroblastoma diagnosis. If the results of our research allow me to say
to some patients that we can successfully fight the disease once it
comes back, that would be the best thing in my career.”

For a complete list of new research grants funded by the Canadian Cancer
Society, visit cancer.ca/Research.

A survivor’s story: Leanne Waddell
Leanne Waddell was only 10 months old when she was diagnosed with
neuroblastoma.

Today, more than 30 years later, Leanne knows how fortunate she is to be
a survivor and to be able to help others going through a cancer
experience. 

“Fighting cancer has always been a mission of mine; it’s something I’ve
always felt strongly about,” Waddell says.

It was Waddell’s babysitter who noticed one evening that the baby girl
had difficulty breathing when she was lying down, but when she sat up
she was fine. When Waddell’s parents rushed her to the hospital, the
doctors found a massive tumour – about the size of a man’s fist -
wrapped around her small spinal cord.

Surgery followed by radiation treatment left Waddell disease-free but
her doctors had warned her parents she would never be able to walk
because of the damage to her spine. Waddell proved them wrong.

And so began her personal fight against cancer. She started volunteering
with the Society as a child, selling daffodils with her mom, and
continued volunteering well into her adult years. Just two months ago
she became the manager of a Canadian Cancer Society unit office. She
also spends time with neuroblastoma patients and their families,
showing her first-hand the many ways this disease can affect children.

She says research projects like Dr Meredith Irwin’s are vital in
advancing our understanding of neuroblastoma. “We know it can be a
deadly disease and it’s especially devastating when it relapses. It’s
important we try to find it and treat it early so maybe it doesn’t get
to that point.”

The effectiveness of treatments for neuroblastoma can also vary. Not all
young patients respond to current treatments, which is why more
research is needed. “Research is the only way we will find better
treatments that will help more children.”

“My experience fuels my drive. I constantly do my best to make an impact
against this disease, especially fundraising for research. Even if it’s
a small difference, it’s still a difference.”

Highlights of other new Canadian Cancer Society research projects
The Society’s long-term goals are to deter, defeat and defy cancer, and
research is a vital part of achieving these goals. The following are
just a few examples of the new research projects we are funding which
will help support Canadians fighting cancer throughout all stages of
their cancer journey.

Deter cancer

        --  Dr Angela Cheung, Toronto, $632,192 - Dr Cheung is studying the
            long-term effects of the drug exemestane on bone health as part
            of a large clinical trial testing whether the drug is effective
            at preventing breast cancer in post-menopausal women at
            increased risk for the disease.  Exemestane is in a class of
            medications that may have negative effects on bone health, and
            this study will provide crucial information about the long-term
            safety of the drug and the risks and benefits for this group of
            women.
        --  Dr Shelley Harris, Toronto, $846,000 - Brominated flame
            retardants are an emerging group of pollutants showing up with
            increasing frequency in the environment. Using blood and urine
            samples of women aged 18 to 44 - some who have cancer and some
            who do not - Dr Harris will investigate whether increased
            exposure to one type of brominated flame retardants,
            specifically polybrominated diphenyl ethers (PBDEs), is
            associated with increased breast cancer risk.

Defeat cancer

        --  Dr Raymond Andersen, Vancouver, $420,527 - Many of the most
            effective anti-cancer drugs have come from nature, and Dr
            Andersen's study looks to the world's oceans as a resource for
            naturally occurring anti-cancer substances. The goal of this
            project is to discover organic compounds that are present in
            marine invertebrates and micro-organisms to develop new drug
            treatments for cancer, with a particular focus on advanced
            stage prostate cancer.
        --  Dr John Dick, Toronto, $432,000 - Dr Dick's lab was the first
            to discover leukemia stem cells (LSCs) and is now working to
            identify genes and other molecular elements that determine how
            blood cells get programmed into LSCs. Using large-scale tests
            in human blood samples, the research team will induce leukemia
            by manipulating the MLL gene and characterize the biological
            effects that lead to the development of LSCs and leukemia.
        --  Dr Aaron Marshall, Winnipeg, $418,977 - Dr Marshall's team is
            focused on understanding molecular processes that lead to
            poorer patient outcomes by helping leukemia cells move out of
            the blood and into bone marrow and lymph nodes. In this study,
            they will focus on components in a molecular pathway called
            PI3K that help leukemia cells "team up" with other cells to
            proliferate and spread, to identify which patients might
            benefit most from chemotherapy that targets this process.
        --  Dr Hanne Ostergaard, Edmonton, $432,000 - Some cancer drugs
            currently in clinical trials block the function of a protein
            called Pyk2 that helps cancer cells move, but Dr Ostergaard's
            team believes this protein also helps the body's natural killer
            cells fight cancer. This study will advance the understanding
            of Pyk2 and another protein called paxillin to help determine
            how to prevent cancer cells from metastasizing and promote
            killer cell function.

Defy cancer

        --  Dr Maru Barrera, Toronto, $566,969 - After overcoming the
            hurdle of childhood brain cancer, some young survivors face the
            additional challenge of weakened social skills due to injury to
            the brain. Dr Barrera's team will evaluate the impact of a new
            program that helps to remediate social skills deficits - a
            program with the potential to improve these children's
            abilities to manage relationships at home and at school.
        --  Dr Ari-Nareg Meguerditchian, Montreal, $124,639 - Taking a
            daily anti-estrogen pill has significantly improved breast
            cancer survival rates, but many patients discontinue the
            treatment prematurely, particularly women 65 and older. Dr
            Meguerditchian's study will use Quebec's drug insurance
            databases to determine how many women in this age group took
            anti-estrogen pills between 1998 and 2005 and predict who is at
            highest risk of stopping the therapy before the end of the
            five-year treatment in order to better support this group of
            patients.

The Canadian Cancer Society fights cancer by doing everything we can to prevent cancer, save lives
and support people living with cancer. Join the fight! Go to fightback.ca to find out how you can help. When you want to know more about cancer,
visit our website at cancer.ca  or call our toll-free bilingual Cancer Information Service at 1 888 939-3333.

/NOTE TO EDITORS: Media Assets accompanying this story are available as
follows:/

Photos:

1)     http://smr.newswire.ca/media/articles/1244/lwaddell-1978.jpg

2)     http://smr.newswire.ca/media/articles/1244/lwaddell-today-with-husband.jpg

Video: http://www.newswire.ca/en/releases/mmnr/smr/110419CCS_Grant_SD_MASTER.mov

/NOTE TO PHOTO EDITORS: A photo accompanying this release is available
at http://photos.newswire.ca. Images are free to accredited members of the media/

SOURCE Canadian Cancer Society (National Office)


Source: newswire



comments powered by Disqus